

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761439Orig2s000

REMS

Risk Evaluation and Mitigation Strategy (REMS) Document

Enoby (denosumab-qbde) REMS

I. Administrative Information

Risks: Severe hypocalcemia
Application Number: BLA 761439
Application Holder: Hikma Pharmaceuticals USA Inc.
Initial REMS Approval: 09/2025

II. REMS Goal

The goal of the Enoby REMS is to mitigate the risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD), including dialysis-dependent patients, associated with Enoby.

Objective 1: Inform healthcare providers on:

- Risk of severe hypocalcemia in patients with advanced chronic kidney disease (estimated glomerular filtration rate [eGFR] < 30 ml/min/1.73 m²)
- Need to assess for presence of chronic kidney disease-mineral bone disorder (CKD-MBD) before initiating Enoby in patients with advanced chronic kidney disease

III. REMS Requirements

To inform healthcare providers about the REMS and the risk and safe use of Enoby, Hikma Pharmaceuticals USA Inc. must disseminate REMS communication materials according to the table below:

Target Audience	Communication Materials & Dissemination Plans
Healthcare providers who are likely to prescribe Enoby	REMS Letters: REMS Letter for Healthcare Providers, REMS Letter for Professional Societies with attachment Prescribing Information. 1. Email REMS Letter for Healthcare Providers within 60 calendar days of the date Enoby is first commercially distributed and again 12 months later. a. If email is undeliverable, the letter will be sent via mail within 30 calendar days of when the email is undeliverable. b. If the first email is marked as unopened, a second email will be sent within 7 calendar days. If the second email is undelivered or marked as unopened, the letter will be mailed within 30 calendar days. 2. Email REMS Letter for Professional Societies within 60 calendar days of the date Enoby is first commercially distributed and again 12 months later through the following professional societies and request the letter or content be provided to their members. If the first email is undeliverable, the REMS letter will be mailed within 30

calendar days. If the first email is marked as unopened, a second email will be sent within 7 calendar days. If the second email is undeliverable or marked as unopened, the REMS letter will be mailed within 30 calendar days.

- a. American Society of Bone Mineral Research
 - b. American College of Rheumatology
 - c. American Association of Clinical Endocrinologists
 - d. Endocrine Society
 - e. American Society of Clinical Oncology
 - f. Bone Health and Osteoporosis Foundation
 - g. North American Menopause Society
 - h. American Academy of Family Physicians
 - i. American College of Physicians
3. Make available via a link from the [REMS Website](#).
 4. Disseminate through field-based sales and medical representatives from the date Enoby is first commercially distributed for the duration of the REMS.
 5. Disseminate and prominently display at Professional Meetings where Hikma Pharmaceuticals USA Inc. has an Enoby commercial presence from the date Enoby is first commercially distributed for the duration of the REMS.

[Patient Guide](#) and Prescribing Information (PI)

1. Disseminate and prominently display at Professional Meetings where Hikma Pharmaceuticals USA Inc. has an Enoby commercial presence from the date Enoby is first commercially distributed for the duration of the REMS.
2. Disseminate through field-based sales and medical representatives during the initial and/or follow-up discussion with healthcare providers from the date Enoby is first commercially distributed for the duration of the REMS. Field-based sales and/or medical representatives to verbally review the risk messages contained in the Patient Guide and PI during the visit with the healthcare provider.

[Website](#)

1. Make the [REMS Website](#) fully operational and all REMS materials available through the website by the date Enoby is first commercially distributed.
 2. Maintain the [REMS Website](#) from the date Enoby is first commercially distributed for the duration of the REMS.
 3. Include a prominent REMS-specific link to the [REMS Website](#) on all product websites for consumers and healthcare providers. The [REMS Website](#) must not link back to the promotional product websites.
-

IV. REMS Assessments Timetable

Hikma Pharmaceuticals USA Inc must submit REMS Assessments at 18 months, 3 years, and 7 years from the date of the initial REMS approval (MM/DD/YYYY). To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting internal covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. Hikma Pharmaceuticals USA Inc. must submit each assessment so that it will be received by the FDA on or before the due date.

V. REMS Materials

The following materials are part of the Enoby REMS:

Training and Educational Materials

Patient:

1. [Patient Guide](#)

Communication Materials

2. [REMS Letter for Healthcare Providers](#)
3. [REMS Letter for Professional Societies](#)

Other Materials

4. [REMS Website](#)

VI. Statutory Elements

This REMS is required under section 505-1 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 355-1) and consists of the following elements:

1. Communication Plan
2. Timetable for Submission of Assessments

What is Enoby?

Enoby (denosumab-qbde) is a prescription medicine used to:

- Treat osteoporosis (thinning and weakening of bone) in women after menopause (“change of life”) who:
 - Are at high risk for fracture (broken bone)
 - Cannot use another osteoporosis medicine or other osteoporosis medicines did not work well
- Treat to increase bone mass in men with osteoporosis who are at high risk for fracture
- Treat bone loss in men who are at high risk for fracture receiving certain treatments for prostate cancer that has not spread to other parts of the body
- Treat bone loss in women who are at high risk for fracture receiving certain treatments for breast cancer that has not spread to other parts of the body
- Treat osteoporosis in men and women who will be taking corticosteroid medicines (such as prednisone) for at least 6 months and are at high risk of fracture

What is the serious risk of Enoby?

Patients with advanced chronic kidney disease, including dialysis-dependent patients, are at risk of severe hypocalcemia (low calcium levels in your blood) following Enoby administration.

Most people with low blood calcium levels do not have symptoms, but some people may have symptoms which include:

- Spasms, twitches, or cramps in your muscles
- Numbness or tingling in your fingers, toes, or around your mouth

Call your doctor right away if you think you may be having any of these symptoms.

What to expect before and during Enoby treatment:

- Talk to your doctor before starting Enoby.
- If you have low blood calcium before you start receiving Enoby, it may get worse during treatment.
- Your low blood calcium must be treated before you receive Enoby.
- Your doctor may prescribe calcium and vitamin D to help prevent low calcium levels in your blood while you take Enoby. Take calcium and vitamin D as your doctor tells you to.
- If you have advanced chronic kidney disease (may or may not be on kidney dialysis), Enoby may increase your risk for severe low calcium levels in your blood, leading to hospitalization, life-threatening events, and death.
- A mineral and bone disorder associated with kidney disease called chronic kidney disease-mineral bone disorder (CKD-MBD) may increase your risk for severe low calcium levels in blood. Before you start Enoby and during treatment, your doctor may need to do certain blood tests to check for CKD-MBD.

If you have advanced chronic kidney disease, your doctor may coordinate your Enoby treatment with a healthcare provider with expertise in CKD-MBD.

Enoby™ REMS FDA Required REMS Safety Information



September 2025

Important Safety Update

Dear Healthcare Provider:

The FDA has required this safety update as part of the Enoby REMS (**R**isk **E**valuation and **M**itigation **S**trategy) to inform healthcare providers about the following **serious risk of Enoby**.

Severe Hypocalcemia in Patients with Advanced Kidney Disease

Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m²), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following Enoby administration.

- Severe hypocalcemia resulting in hospitalization, life-threatening events, and fatal cases have been reported.
- To minimize the risk of hypocalcemia in patients with advanced chronic kidney disease (CKD):
 - Evaluate for the presence of chronic kidney disease mineral and bone disorder (CKD-MBD) with intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25 (OH)₂ vitamin D prior to decisions regarding Enoby treatment.
 - Consider assessing bone turnover status (serum markers of bone turnover or bone biopsy) to evaluate the underlying bone disease that may be present.
 - Monitor serum calcium weekly for the first month after Enoby administration and monthly thereafter.
 - Coordinate care with healthcare providers with expertise in CKD-MBD for patients with advanced chronic kidney disease.

Role of the Healthcare Provider

- ✓ **Provide** each patient with a copy of the **Patient Guide**.
- ✓ **Review** information in the **Patient Guide** with each patient, including the serious risk of Enoby and the symptoms of severe hypocalcemia.
- ✓ **Advise** each patient to seek prompt medical attention if they have signs or symptoms of severe hypocalcemia.

This letter does not contain the complete safety profile for Enoby. Please review the Prescribing Information enclosed. All Enoby REMS materials are also available at www.enobyrems.com or by contacting your local Hikma Sales Representative.


Reporting Adverse Events

To report Adverse Reactions with Enoby, please call Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or report the event at FDA MedWatch.

Sincerely,

Hikma Pharmaceuticals USA Inc. – Injectables and Biosimilars

Enoby™ REMS FDA Required REMS Safety Information



September 2025

Important Safety Update

Dear [Professional Society]:

The FDA has required Hikma Pharmaceuticals USA Inc. to distribute this safety update to your organization as part of our Enoby REMS (**R**isk **E**valuation and **M**itigation **S**trategy). We request that you inform your members about the following **serious risk of Enoby**.

Severe Hypocalcemia in Patients with Advanced Kidney Disease

Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m²), including dialysis-dependent patients, are at a greater risk of severe hypocalcemia following Enoby administration.

- Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported.
- To minimize the risk of hypocalcemia in patients with advanced chronic kidney disease (CKD):
 - Evaluate for the presence of chronic kidney disease mineral and bone disorder (CKD-MBD) with intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25 (OH)₂ vitamin D prior to decisions regarding Enoby treatment.
 - Consider assessing bone turnover status (serum markers of bone turnover or bone biopsy) to evaluate the underlying bone disease that may be present.
 - Monitor serum calcium weekly for the first month after Enoby administration and monthly thereafter.
 - Coordinate care with healthcare providers with expertise in CKD-MBD for patients with advanced chronic kidney disease.

Role of the Healthcare Provider

- ✓ **Provide** each patient with a copy of the **Patient Guide**.
- ✓ **Review** information in the **Patient Guide** with each patient, including the serious risk of Enoby and the symptoms of severe hypocalcemia.
- ✓ **Advise** each patient to seek prompt medical attention if they have signs or symptoms of severe hypocalcemia.

This letter does not contain the complete safety profile for Enoby. Please review the Prescribing Information enclosed. All Enoby REMS materials are also available at www.enobyrems.com or by contacting your local Hikma Sales Representative.

Reporting Adverse Events

To report Adverse Reactions with Enoby, please call Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or report the event at FDA MedWatch.

Sincerely,

Hikma Pharmaceuticals USA Inc. – Injectables and Biosimilars



Enoby™ REMS

What is the Enoby REMS (Risk Evaluation and Mitigation Strategy)?

The Enoby REMS (Risk Evaluation and Mitigation Strategy) is a safety program required by the Food and Drug Administration. The purpose of the Enoby REMS is to inform healthcare providers and patients about the risk of severe hypocalcemia in patients with advanced chronic kidney disease, including dialysis-dependent patients, following Enoby administration.

The Enoby REMS materials are designed to inform healthcare providers and their patients about the risk of severe hypocalcemia associated with Enoby and include the below materials. It is important that you discuss with your patients the information included in the **Patient Guide**.

- REMS Letter for Healthcare Providers
- Prescribing Information
- Patient Guide

Reporting Adverse Events

To report adverse events with Enoby, please call Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or report the event at [FDA Medwatch](#).

Resources

Resources for Prescribers

[REMS Letter for Healthcare Providers](#)

[Prescribing Information](#)

[Patient Guide](#)

Resources for Patients

[Patient Guide](#)

To learn more about Enoby, read the [Important Safety Information](#) and use the links to access Enoby REMS materials.

The site is for US Residents only

[Important Safety Information](#)

[Prescribing Information](#)



Contact Us

If you have a question about the REMS, clinical inquiry, or would like to report an adverse event related to Enoby, call 1-877-845-0689.

© 2025 Hikma Pharmaceuticals USA Inc. All rights reserved.

[Privacy Policy](#)

[Terms of Use](#)

[Contact Us](#)

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

THERESA E KEHOE
10/29/2025 11:40:27 AM

CHRISTY L OSGOOD
10/29/2025 01:06:17 PM